Kontakt 2020, 22(4):285-290 | DOI: 10.32725/kont.2020.039

Determinants of quality life of patients with psoriasis treated with biologicsSocial Sciences in Health - Original article

Slávka Mrosková1 *,Viera Konečná 2, Gabriela Kuriplachová1, Elena Gurková3
1 University of Prešov, Faculty of Health Care, Department of Nursing, Prešov, Slovak Republic
2 Faculty Hospital J. A. Reiman in Prešov, Department of Dermatovenerology, Prešov, Slovak Republic
3 Palacký University, Faculty of Health Sciences, Department of Nursing, Olomouc, Czech Republic

Aim: The aim of the study was to assess the quality life of patients with psoriasis treated with biologics, and to analyze the various factors that determine it.

Methods: The cross-sectional study was realized with 117 patients at the Centre for Biologic Therapy in Slovakia. The factors analyzed were: Dermatology Life Quality Index (DLQI), The Brief Illness Perception Questionnaire (BIPQ), General Anxiety Disorder-7 (GAD-7), Psoriasis Area Severity Index (PASI), localization of skin changes, duration of the disease, length of use of biologics, BMI.

Results: Mean score of DLQI was 9.03 (SD = 6.59, range = 2-23). DLQI significantly correlates with PASI (r = 0.347), length of use of biologics (r = -0.286), illness perception (r = 0.557) and anxiety (r = 0.338). Hierarchical regression analysis showed that PASI (β = 0.252) and illness perception (β = 2.209) were significant predictors of a patient's quality life.

Conclusions: The findings of study indicate that the quality life of psoriatic patients treated with biologics is determined by the disease severity and illness perception. Therefore it is very important to include a psychosocial dimension (assessment, effective intervention) in the care of these patients.

Keywords: Anxiety; Disease severity; Illness perception; Psoriasis vulgaris; Quality of life

Received: June 11, 2020; Revised: October 2, 2020; Accepted: October 20, 2020; Prepublished online: October 29, 2020; Published: December 15, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mrosková S, Kuriplachová G, Gurková E. Determinants of quality life of patients with psoriasis treated with biologics. Kontakt. 2020;22(4):285-290. doi: 10.32725/kont.2020.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, et al. (2017). A systematic review of the use of quality-of-life Instruments in randomized controlled trials for psoriasis. Br J Dermatol 176(3): 577-593. DOI: 10.1111/bjd.14788. Go to original source... Go to PubMed...
    2. Broadbent E, Petrie KJ, Main J, Weinman J (2006). The brief illness perception questionnaire. J Psychosom Res 60(6): 631-637. DOI: 10.1016/j.jpsychores.2005.10.020. Go to original source... Go to PubMed...
    3. Broadbent E, Wilkes C, Koschwanez H, Weinman J, Norton S, Petrie KJ (2015). A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. Psychol Health 30(11): 1361-1385. DOI: 10.1080/08870446.2015.1070851. Go to original source... Go to PubMed...
    4. Calara PS, Norlin JM, Althin R, Carlsson KS, Schmitt-Egenolf M (2016). Health care Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice. Bio Drugs 30(2): 145-151. DOI: 10.1007/s40259-016-0163-8. Go to original source... Go to PubMed...
    5. Coates LC, Helliwell PS (2017). Psoriatic arthritis: state of the art review. Clin Med (Lond) 17(1): 65-70. DOI: 10.7861/clinmedicine.17-1-65. Go to original source... Go to PubMed...
    6. Costa ECV, Vale S, Sobral M, Graça Pereira M (2016). Illness perceptions are the main predictors of depression and anxiety symptoms in patients with chronic pain. Psychol Health Med 21(4): 483-495. DOI: 10.1080/13548506.2015.1109673. Go to original source... Go to PubMed...
    7. Daudén E, Herrera E, Puig L, Sánchez-Carazo JL, Toribio J, Perulero N (2013). Impact of active and stable psoriasis on health-related quality of life: The PSO-LIFE study. Actas Dermosifiliogr 104(8): 685-693. DOI: 10.1016/j.adengl.2013.02.008. Go to original source... Go to PubMed...
    8. Dimitrov D, Matusiak Ł, Szepietowski JC (2019). Stigmatization in Arabic psoriatic patients in the United Arab Emirates - a cross sectional study.PostepyDermatolAlergol36(4): 425-430. DOI: 10.5114/ada.2018.80271. Go to original source... Go to PubMed...
    9. Ferreira BI, Abreu JL, Reis JP, Figueiredo AM (2016). Psoriasis and Associated Psychiatric Disorders. A systematic Review on Etiopathogenesis and Clinical Correlation. J Clin Aesthet Dermatol 9(6): 36-43.
    10. Finlay AY, Khan GK (1994). Dermatology Life Quality Index (DLQI) - A simple practical measure for routine clinical use. Clin Exp Dermatol 19(3): 210-216. DOI: 10.1111/j.1365-2230.1994.tb01167.x. Go to original source... Go to PubMed...
    11. Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP (2017). The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol 31(5): 798-807. DOI: 10.1111/jdv.13891. Go to original source... Go to PubMed...
    12. Fortune DG, Richards HL, Griffiths CE, Main CJ (2002). Psychological stress, distress and disability in patients withpsoriasis: Consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol 41(Pt 2): 157-174. DOI: 10.1348/014466502163949. Go to original source... Go to PubMed...
    13. Freire M, Rodríguez J, Möller I, Valcárcel A, Tornero C, Díaz G, et al. (2011). Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Reumatol Clin 7(1): 20-26. DOI: 10.1016/j.reuma.2010.03.003. Go to original source... Go to PubMed...
    14. Hagger MS, Orbell S (2003). A meta-analytic review of the common-sense model of illness representations. Psychol Health 18(2): 141-184. DOI: 10.1080/088704403100081321. Go to original source...
    15. Higgins E (2017). Psoriasis. Medicine 45(6): 368-378. DOI: 10.1016/j.mpmed.2017.03.010. Go to original source...
    16. Kaaz K, Szepietowski JC, Matusiak L (2019). Sleep quality among adult patients with chronic dermatoses. Adv Dermatol Allergol 36(6): 659-666. DOI: 10.5114/ada.2019.84007. Go to original source... Go to PubMed...
    17. Kotsis K, Voulgari PV, Tsifetaki N, Drosos AA, Carvalho AF, Hyphantis T (2014). Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjögren's syndrome compared to systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 34(12): 1671-1681. DOI: 10.1007/s00296-014-3008-0. Go to original source... Go to PubMed...
    18. Kotsis K, Voulgari PV, Tsifetaki N, Machado MO, Calvalho AF, Creed F, et al. (2012). Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken) 64(10): 1593-1601. DOI: 10.1002/acr.21725. Go to original source... Go to PubMed...
    19. Łakuta P, Przybyla-Basista H (2017). Toward a better understanding of social anxiety and depression in psoriasis patients: The role of determinants, mediators, and moderators. J Psychosom Res. 94: 32-38. DOI: 10.1016/j.jpsychores.2017.01.007. Go to original source... Go to PubMed...
    20. Łakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezińska-Wcisło L, Słomian A (2018). Associations between site of skin lesions and depression, social anxiety, body-related emotions and feelings of stigmatization in psoriasis patients. Postepy Dermatol Alergol 35(1): 60-66. DOI: 10.5114/pdia.2016. 62287. Go to original source... Go to PubMed...
    21. Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, et al. (2017). Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol 176(4): 1028-1034. DOI: 10.1111/bjd.14833. Go to original source... Go to PubMed...
    22. Leventhal H, Diefenbach M, Leventhal EA (1992). Illness cognition: Using common sense to understand treatment adherence and affect cognition interactions. Cognitive Therapy and Research 16(2): 143-163. DOI: 10.1007/BF01173486. Go to original source...
    23. Mattei PL, Corey KC, Kimball AB (2014). Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychologicalburden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 28(3): 333-337. DOI: 10.1111/jdv.12106. Go to original source... Go to PubMed...
    24. Menting SP, Sitaram AS, Bonnerjee-van der Stok HM, de Rie MA, Hooft L, Spuls PI (2014). Drug survival is not significantly different between biologics in patients with Psoriasis vulgaris: a single-centre database analysis. Br J Dermatol 171(4): 875-883. DOI: 10.1111/bjd.13001. Go to original source... Go to PubMed...
    25. Norris D, Photiou L, Tacey M, Dolianitis C, Varigos G, Foley P, et al. (2017). Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatolog Treat 28(8): 731-736. DOI: 10.1080/09546634.2017.1329501. Go to original source... Go to PubMed...
    26. Obradors M, Blanch C, Comellas M, Figueras M, Lizan L (2016). Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Qual Life Res 25(11): 2739-2754. DOI: 10.1007/s11136-016-1321-7. Go to original source... Go to PubMed...
    27. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013). Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J Invest Dermatol 133(2): 377-385. DOI: 10.1038/jid.2012.339. Go to original source... Go to PubMed...
    28. Petraškiene R, Valiukevičiene S, Macijauskiene J (2016). Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis. Medicina (Kaunas) 52(4): 238-243. DOI: 10.1016/j.medici.2016.07.001. Go to original source... Go to PubMed...
    29. Puig L, Thom H, Mollon P, Tian H, Ramakrishma GS (2017). Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 31(2): 213-220. DOI: 10.1111/jdv.14007. Go to original source... Go to PubMed...
    30. Reich K, Griffiths CE (2008). The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 300(10): 537-544. DOI: 10.1007/s00403-008-0885-7. Go to original source... Go to PubMed...
    31. Richards HL, Fortune DG, Griffiths CE, Main CJ (2001). The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 50(1): 11-15. DOI: 10.1016/s0022-3999(00)00210-5. Go to original source... Go to PubMed...
    32. Salemi S, Ghasemi A, Arefi M (2016). The relationship between illness perception, depression and quality of life in patients with psoriasis who referred to Haj Daie dermatology clinic in Kermanshah. Der Pharmacia Lettre 8(3): 85-89.
    33. Spitzer RL, Kroenke K, Williams JB, Löwe B (2006). Brief Measure for Assessing Generalized Anxiety Disorder. The GAD-7. Arch Intern Med 166(10):1092-1097. DOI: 10.1001/archinte.166.10.1092. Go to original source... Go to PubMed...
    34. Takahashi H, Iinuma S, Tsuji H, Honma M, Iizuka H (2014). Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients. J Dermatol 41(8): 686-689. DOI: 10.1111/1346-8138.12544. Go to original source... Go to PubMed...
    35. Wahl AK, Robinson HS, Langeland E, Larsen MH, Krogstad AL, Moum T (2014). Clinical characteristics associated with illness perception in psoriasis. Acta Derm Venereol 94(3): 271-275. DOI: 10.2340/00015555-1673. Go to original source... Go to PubMed...
    36. World Health Organization (2016). Global report on Psoriasis, 48 p.
    37. Wu CY, Chang YT, Juan CK, Shen JL, Lin YP, Shieh JJ, et al. (2016). Depression and Insomnia in Patients with Psoriasis and Psoriatic Arthritis Taking Tumor Necrosis Factor Antagonists. Medicine (Baltimore) 95(22): e3816. DOI: 10.1097/MD.0000000000003816. Go to original source... Go to PubMed...
    38. Zhang M, Hong L, Zhang T, Lin Y, Zheng S, Zhou X, et al. (2016). Illness perceptions and stress: mediators between disease severity and psychological well-being and quality of life among patients with Crohn's disease. Patient Prefer Adherence 10: 2387-2396. DOI: 10.2147/PPA.S118413. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content